Other secondary outcomes | Mean difference (SD) or frequency (%) | p-value | |
---|---|---|---|
Viral load < 50 copies, n (%) | |||
CG | 44 (59.5) | 0.038* | |
AG | 61(69.3) | ||
AMG | 67 (77.9) | ||
Mean LVL | |||
CG | -0.75 (2.47) | Â | |
AG | -1.17 (2.32) | 0.564 | |
AMG | -2.56 (3.17) | 0.022* | |
Mean increment in white blood cell count | |||
CG | 1.21 (2.67) | Â | |
AG | 1.14 (2.29) | 0.080 | |
AMG | 2.08 (4.60) | 0.003* | |
Mean increment in platelet levels | |||
CG | -7.67 (7.73) | Â | |
AG | -15.68 (10.06) | 0.952 | |
AMG | 11.04 (3.29) | 0.025* | |
Mean plasma levels of efavirenz and nevirapine (mg/l) (SD) | |||
EFV (n = 67) | Baseline | 4.66 (0.76) | 0.987 |
Week 1 | 4.66 (0.76) | ||
Week 2 | 4.51 (0.68) | ||
NVP (n = 38) | Baseline | 7.86 (1.21) | 0.991 |
Week 1 | 7.81 (1.05) | ||
Week 2 | 7.67 (0.94) |